Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)


Organizer(s) A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel
March 6—10, 2016
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Discounted Abstract Deadline: Nov 5, 2015
Abstract Deadline: Dec 8, 2015
Scholarship Deadline: Nov 5, 2015
Discounted Registration Deadline: Jan 7, 2016

Sponsored by Regeneron Pharmaceuticals, Inc.

Joint Meeting: Antibodies as Drugs (X2)

Summary of Meeting:
The past decade has seen tremendous developments in novel cancer therapies, through targeting of tumor cell-intrinsic pathways whose activity is linked to genetic alterations, as well as the targeting of tumor cell-extrinsic factors such as growth factors. Remarkable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies, possibly due to the lack of T cell repertoire with specificity against cancer antigens. This creates the need for effective means of expanding the T cells in patients via immunization, i.e., cancer vaccines. Much progress has been made in recent years in this regard, and several phase III clinical trials testing various approaches to therapeutic vaccination are ongoing. The challenge for next-generation vaccines is to resolve the discrepancy between the immune and clinical efficacy measured by the rate of cancer rejection. The future immunotherapy of cancer lies in combination approaches targeting T cells as well as cancer genes to combat underlying inflammation. Spectacular progress has been made in these two parallel fields, i.e., cancer genomics and genetics, and tumor immunology. It is time now to link these fields to enable the linking of genetic alterations with the type of immune response. The meeting will therefore host cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists and vaccinologists. It will discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigen presentation and T cell biology might enable development of next-generation curative therapies for patients with cancer.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 10 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 11 in order to fully experience the meeting.

SUNDAY, MARCH 6

16:00—20:00
Arrival and Registration

Macdonald Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Macdonald Foyer

MONDAY, MARCH 7

07:00—08:00
Breakfast

Frontenac
07:30—08:00
Poster Setup

Frontenac
08:00—17:00
Poster Viewing

Frontenac
08:00—10:00
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA

Ronald N. Germain, NIAID, National Institutes of Health, USA
Visualizing and Deconstructing Immune Responses in situ

Sebastian Amigorena, Institut Curie, France
Regulation of Antigen Cross Presentation and Anti Tumor Immune Responses


Following Session is for Antibodies as Drugs (X2)

08:00—10:00
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.

Macdonald ABC
* Peter D. Senter, Seattle Genetics Inc., USA

Rakesh K. Jain, Massachusetts General Hospital and Harvard Medical School, USA
Reengineering the Tumor Microenvironment to Enhance Cancer Treatment: Bench to Bedside

Andreas G. Plückthun, University of Zürich, Switzerland
Protein Engineering Approaches to New Biologicals

10:00—10:20
Coffee Break

Macdonald Foyer
10:20—11:30
Antigens
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Synergy of Therapeutic Vaccination against HPV16 Oncogenic Proteins and Standard Chemotherapeutics

Victor H. Engelhard, University of Virginia, USA
Phosphopeptides Displayed by MHC Molecules as New-Generation Cancer Vaccine Targets


Following Session is for Antibodies as Drugs (X2)

10:20—11:45
Getting Antibodies to Where They Need to Go
Meeting has ended...abstracts no longer viewable online.
The session will cover some of the major underlying challenges facing the field of antibody based therapeutics.

Macdonald ABC
* Peter D. Senter, Seattle Genetics Inc., USA

James M. Olson, Fred Hutchinson Cancer Research Center, USA
Micro Needle Technologies for Intratumoral Drug Delivery and Combination Screening

Alison M. Betts, Pfizer, Inc., USA
PK/PD Modeling for Macromolecular Drug Delivery

Richard Tavaré, University of California, Los Angeles, USA
Short Talk: Noninvasive Detection of Tumor-Infiltrating Lymphocytes using Anti-CD8 Immuno-PET: Impact of Protein Dose

11:30—12:30
Lunch

Frontenac
12:00—14:30
Poster Session 1

Frontenac
14:30—16:30
Workshop 1: Molecular Vaccines

Macdonald DEF
* Darrell J. Irvine, Massachusetts Institute of Technology, USA

* Yvette van Kooyk, Vrije University Medical Center, Netherlands

Tomasz Ahrends, Netherlands Cancer Institute, Netherlands
Combined CD27-Costimulation and PD-1-Inhibition Recapitulates CD4+ T-cell Help in Therapeutic Vaccination Against Cancer

Suresh de Silva, Heat Biologics Inc., USA
Combination Immunotherapy: T-cell Costimulation (OX40L, TL1A, 4-1BBL and ICOSL) Secreted Locally by Gp96-Ig Vaccines, Elicits Robust Antigen-Specific, Memory T Cell Responses and Tumor Elimination

Christa I. DeVette, University of Oklahoma Health Sciences Center, USA
Development of Tools to Evaluate Anti-tumor Immunity

James Moon, University of Michigan, USA
Nanodisc-Based Peptide Vaccines for Personalized Cancer Immunotherapy

Geoffrey Lynn, National Institutes of Health, USA
Self-Assembling Nanoparticles Codelivering Peptide Neoantigens and TLR-7/8 Agonists Enhance the Breadth and Potency of Anti-Tumor Immunity

Naveen Mehta, Massachusetts Institute of Technology, USA
Utilizing Protein Carriers to Engineer Cancer Vaccines with Improved Potency

Kristen Radford, University of Queensland, Australia
Targeting Antigen to Human CD141+ Dendritic Cells via CLEC9A in vitro and in vivo Confers Effective Cross-Presentation to CD8+ T Cells


Following Session is for Antibodies as Drugs (X2)

14:30—16:30
Workshop 1: Novel Constructs

Macdonald ABC
* Dennis R. Benjamin, Seattle Genetics Inc., USA

Jonathan H. Davis, Bristol-Myers Squibb, USA
Synergy Generates Picomolar Potency and a High Resistance Barrier in Combinectin, a Novel Trispecific HIV-1 Entry Inhibitor with Clinical Promise

Eric Hatterer, NovImmune.SA, Switzerland
Characterizing the Preclinical Candidate, NI-1701, a CD47 Targeting Bispecific Antibody in Development for the Treatment of B Cell Lymphomas and Leukemias

Paul A. Moore, MacroGenics, USA
MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors

Marijn A. Gillissen, Aimm Therapeutics / AMC, Netherlands
Donor-Derived B Cells Produce Potent AML-Specific Antibodies that Recognize a Novel Tumor-Specific Antigen and Mediate Graft-Versus- Leukemia Immunity

Yu-Sang Sabrina Yang, Massachusetts Institute of Technology, USA
Targeting Immunomodulators to Lymphocytes Via Amphiphilic Gold Nanocarriers

Travis Young, California Institute for Biomedical Research, USA
Antibody-based Control of CAR-T Cell Therapy

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Antigen-Presenting Cells
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* Jacques F. Banchereau, The Jackson Laboratory for Genomic Medicine, USA

Julie Magarian Blander, Weill Cornell Medicine, Cornell University, USA
Regulation of Antigen Cross-presentation in Dendritic Cells

A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA
Dendritic Cells as Cancer Vaccines

Matthew F. Krummel, University of California, San Francisco, USA
T Cell-Antigen Presenting Dynamics in the Tumor Microenvironment

Brian J. Francica, Johns Hopkins University School of Medicine, USA
Short Talk: Radio-resistant Stromal Cells Initiate the Innate Response to Cyclic Dinucleotides


Following Session is for Antibodies as Drugs (X2)

17:00—19:15
Engineering Antibody Function
Meeting has ended...abstracts no longer viewable online.

Macdonald ABC
* Alison M. Betts, Pfizer, Inc., USA

Margaret Ellen Ackerman, Dartmouth College, USA
Evolution of Antibodies for Optimized Effector Function Activities

Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
IgA as Alternative Therapeutic Antibody: Combination with IgG, Half-Life Extension and More

Sarel J. Fleishman, Weizmann Institute of Science, Israel
De novo Design of Novel Protein Functions

Paul W. H. I. Parren, Genmab B.V., Netherlands
Functional Aspects of Antigen- and Fc-Dependent IgG Hexamer Formation

19:00
On Own for Dinner


TUESDAY, MARCH 8

07:00—08:00
Breakfast

Frontenac
08:00—11:15
Priming Effector T Cells
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* Sebastian Amigorena, Institut Curie, France

Victor Appay, INSERM U1135, France
Impaired Induction of High-Quality Effector CD8+ T-Cells in Old Humans

Luca Gattinoni, NCI, National Institutes of Health, USA
Generation of Long-Lived Cancer Antigen-Specific CD8+ T Cell Memory

Pamela S. Ohashi, Princess Margaret Cancer Centre, Canada
Novel Subsets Involved in T Cell Anti-Tumor Immunity

Ugur Sahin, TRON – Translationale Oncology, Germany
Exploiting Antiviral Immune Mechanisms for Cancer Immunotherapy

Dixon Dorand, Case Western Reserve University, USA
Short Talk: Cyclin Dependent Kinase 5 (CDK5) Controls PD-L1 Expression via Phosphorylation of IRF2BP2 in Murine Medulloblastoma and CDK5 Deficiency Results in CD4+ Dependent T-Cell Rejection

Alison Taylor, University of Cambridge, UK
Short Talk: Glycogen Synthase Kinase 3 Inhibition Blocks PD-1 Expression via Increased Tbet Expression for Enhanced CD8+ Cytolytic T-Cell Responses


Following Session is for Antibodies as Drugs (X2)

08:00—11:00
B Cell Biology and Antibody Repertoires
Meeting has ended...abstracts no longer viewable online.
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.

Macdonald ABC
* David A. Scheinberg, Memorial Sloan-Kettering Cancer Center, USA

George Georgiou, University of Texas at Austin, USA
Systematic Characterization and Comparative Analysis of Antibody Repertoires

Pavel Tolar, Francis Crick Institute, UK
EMBO Young Investigator Lecture: Regulation of Antibody Responses by B Cell Mechanical Activity

Laura M. Walker, Adimab, USA
Rapid and Large-Scale Isolation of Potent Neutralizing Antibodies from a Survivor of the 2014 Ebola Virus Outbreak

Paul A. Ramsland, RMIT University, Australia
Short Talk: Unanticipated Global Changes in IgG1 from Mutation of FcRn Binding Site Residues

Sai T. Reddy, ETH Zurich, Switzerland
Short Talk: Correlations of Antibody Response Phenotype to Genotype Revealed by Molecular Amplification Fingerprinting

09:20—09:40
Coffee Break

Macdonald Foyer
11:15—13:00
Poster Setup

Frontenac
13:00—22:00
Poster Viewing

Frontenac
11:15—14:30
On Own for Lunch

14:30—16:30
Workshop 2: Cell-Based Vaccines

Macdonald DEF
* Robert A. Seder, NIAID, National Institutes of Health, USA

* Masaki Terabe, NCI, National Institutes of Health, USA

Andres Alloatti, Institut Curie, France
Dissecting Cross-Presentation in Dendritic Cells: Who, How and Why?

Anja C. Bloom, NCI, National Institutes of Health, USA
INT230-6 Administered Intratumorally Converts Tumor to an Endogenous Vaccine in Mouse Colon Cancer

Agamemnon Antoniou Epenetos, Imperial College London, UK
Creation of Biological Microparticles from Mesenchymal Stem Cell (MSC) to Deliver Vaccines and other Therapeutics such as Proteins or Nucleic Acids

Simon Heidegger, Klinikum Rechts der Isar, Technical University Munich, Germany
Activation of the Cytosolic RNA Receptor RIG-I in Tumor and Immune Cells Triggers Efficient Anti-Tumor Immunity and Synergizes with Checkpoint Blockade

Kavya Rakhra, Massachusetts Institute of Technology, USA
Combination Immunotherapy of an Autochthonous Murine Lung Cancer Model Expressing Human CEA as a Tumor-Associated Self-Antigen

Yvette van Kooyk, Vrije University Medical Center, Netherlands
Vaccines Facilitating Cross-Presentation for the Induction of Tumor-Immunity Overcoming Tumor Induced Suppression

Megan C. Wise, University of Pennsylvania, USA
Various forms of CD40L Encoded as an Immune Plasmid Adjuvant Generate Unique Anti-HPV DNA Vaccine Induced Responses

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Reprogramming T Cell Memory
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* Victor Appay, INSERM U1135, France

Rafi Ahmed, Emory University School of Medicine, USA
Features of Memory CD8+ T Cells in Chronic Infection

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Lineage Relationship of Effector and Memory T Cells

Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting Immunometabolism as a Means of Enhancing Immunotherapy

Madhusudhanan Sukumar, NCI, National Institutes of Health, USA
Short Talk: Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for TCR and CAR based Adoptive Immunotherapy of Cancer


Following Session is for Antibodies as Drugs (X2)

17:00—19:15
Novel Antibody Constructs
Meeting has ended...abstracts no longer viewable online.

Macdonald ABC
* Anna M. Wu, University of California, Los Angeles, USA

David A. Scheinberg, Memorial Sloan-Kettering Cancer Center, USA
Drugging Intracellular Targets with Vaccines and Human Therapeutic TCR Mimic Antibodies

Dennis R. Benjamin, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy

Birgit Schoeberl, Merrimack Pharmaceuticals, USA
Multispecific Antibody Therapeutics Derived from Systems Biology and Computational Modeling

John C. Williams, Beckman Research Institute at City of Hope, USA
Functionalization of MAbs Using Mechanical Bonds

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac
19:30—22:00
Poster Session 2

Frontenac

WEDNESDAY, MARCH 9

07:00—08:00
Breakfast

Frontenac
08:00—11:00
Cancer Vaccines
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* Cornelis J. M. Melief, Leiden University Medical Center, Netherlands

Laurence Zitvogel, Institut Gustave Roussy, France
Molecular Mechanisms of Cancer Antigen Presentation at the Tumor Site

Thomas W. Dubensky, Jr., Aduro Biotech, USA
Insights from Listeria monocytogenes for the Development of Vector- and Small Molecule-Based Cancer Immunotherapy Strategies

Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, USA
Advances in Oncolytic Virus Immunotherapy

Sandra Demaria, Weill Cornell Medical College, USA
In situ Vaccination by Radiation Therapy

Rupert Kenefeck, Immunocore Ltd., UK
Short Talk: Overcoming Immune Regulation to Kill Cancers: ImmTAC Targeting and Checkpoint Inhibition


Following Session is for Antibodies as Drugs (X2)

08:00—11:00
Targeted Delivery for Imaging and Therapy
Meeting has ended...abstracts no longer viewable online.

Macdonald ABC
* Alan J. Korman, Bristol-Myers Squibb, USA

Anna M. Wu, University of California, Los Angeles, USA
Detecting Tumor and Immune Cell Responses to Therapy Using ImmunoPET

Katherine A. Vallis, University of Oxford, UK
Antibody-Based Radiotherapy and Radiodetection of Cancer

Colin E. Correnti, Fred Hutchinson Cancer Research Center, USA
Tumor Paint and Penetrating Peptide Drug Conjugates

Jacob Petersburg, University of Minnesota, USA
Short Talk: Utilizing Prosthetic Antigen Receptors (PARs) for Anti-EpCAM Cell-directed Immunotherapy

David T. Rodgers, Calibr, USA
Short Talk: Antibody Based Switches Control the Activation and Targeting of CAR T Cells for B Cell Malignancies

09:20—09:40
Coffee Break

Macdonald Foyer
11:00—13:00
Poster Setup

Frontenac
13:00—22:00
Poster Viewing

Frontenac
11:00—17:00
On Own for Lunch


Following Session is for Antibodies as Drugs (X2)

14:30—16:30
Workshop 2: Novel Designs and Therapeutics

Macdonald Ballroom
* Margaret Ellen Ackerman, Dartmouth College, USA

Hamid Bassiri, Children's Hospital of Philadelphia, USA
Novel Invariant Natural Killer T Cell-Based Immunotherapies for Cancer

Hanke Matlung, Sanquin Research and Landsteiner Laboratory, Netherlands
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis

Sheena N. Smith, University of Zurich, Switzerland
Targeted Adenoviral Delivery of Protein-Based Therapeutics to the Tumor Microenvironment

Michael W. Munks, Oregon Health & Science University, USA
Major Histocompatibility Class I - Antibody Fusion Proteins (pMHCI-IgGs) that Link B16 Melanoma Cells to Cytomegalovirus-Specific CD8 T Cells Control B16 Melanoma in vivo

Huafeng Xu, D.E. Shaw Research LLC, USA
Divergent Sequences Stabilize Similar Antigen-Binding Conformations in the Affinity Maturation of a Broadly Neutralizing Influenza Antibody Lineage

David P. Humphreys, UCB Pharma, UK, UK
Statistical Design for Effector Function Engineering of Hexameric Fc Domains

Andre BH Choo, Bioprocessing Technology Institute, Singapore
Glycan: A Sweet Opportunity for Antibody Discovery

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Antibodies for Checkpoint Blockade (Joint)
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Madhav V. Dhodapkar, Yale School of Medicine, USA

Alan J. Korman, Bristol-Myers Squibb, USA
Antitumor Activity of Immunomodulatory Antibodies

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy: Mechanism-Based Biomarkers and New Frontiers

John J. Miles, QIMR Berghofer Medical Research Institute, Australia
CD96/TIGIT/DNAM Pathway and Tumor Rejection

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac
19:30—22:00
Poster Session 3

Frontenac

THURSDAY, MARCH 10

07:00—08:00
Breakfast

Frontenac
08:00—11:15
Antibodies as Co-Factors (Joint)
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Laurence Zitvogel, Institut Gustave Roussy, France

Madhav V. Dhodapkar, Yale School of Medicine, USA
Harnessing Host Response to Premalignancy in Prevention of Cancer

Carl G. Figdor, Radboud University Medical Center, Netherlands
Dendritic Cell Based Cancer Immunotherapy

Ira Mellman, Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy

Nina Bhardwaj, Mt. Sinai Hospital, USA
Modulation of Innate Immunity in Cancer

Kelly D. Moynihan, Massachusetts Institute of Technology, USA
Short Talk: Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity

Rony Dahan, Rockefeller University, USA
Short Talk: Improved Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Abs by Selective FcgammaR-Engagement

09:20—09:40
Coffee Break

Macdonald Foyer
11:15—14:30
On Own for Lunch

14:30—16:30
Workshop 3: Peptides as Vaccines

Macdonald DEF
* Robert D. Schreiber, Washington University School of Medicine, USA

Anne-Mette Bjerregaard, Technical University of Denmark, Denmark
MuPeXI: A Tool for Prediction of Neo-Epitopes from Tumor Sequencing Data

Gustav Gaudernack, Ultimovacs AS/Norwegian Radium Hospital, Norway
UV1 – A Second-Generation, Peptide-Based, Therapeutic Cancer Vaccine (TCV) Targeting the Reverse Transcriptase Subunit of Human Telomerase (hTERT

Matthew M. Gubin, Washington University in St. Louis, USA
Tumor-Specific Mutant Antigens in Cancer Immunotherapy

Bruno Laugel, Adaptimmune Ltd, UK
Safety Assessment of DNA Methyl Transferase Inhibitors in Combination with NY-ESO T-cell Therapy.

Aizea Morales Kastresana, NCI, National Institutes of Health, USA
Optimization of Extracellular Vesicle Labels for NanoFACS

Hideho Okada, University of California, San Francisco, USA
Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation

Jeffrey Ward, Washington University in St. Louis, USA
Tumor Mutant Antigen-Specific CD8+ T-cells Require CD4+ T-cell Help to Induce Tumor Regression

Klaus Früh, Oregon Health & Science University, USA
CMV-induced MHC-II and MHC-E-Restricted CD8+ T Cells: A Role in Cancer Immunotherapy

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—18:45
Linking Cancer Genetics and Genomics with Immunity
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* Hyam I. Levitsky, Juno Therapeutics, USA

Jacques F. Banchereau, The Jackson Laboratory for Genomic Medicine, USA
Genomics of Human Immune Response

Robert D. Schreiber, Washington University School of Medicine, USA
Cancer-Specific Mutations as Tumor Rejection Antigens

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Targeting Tumor Neoantigens: Developing Personalized Cancer Vaccines


Following Session is for Antibodies as Drugs (X2)

17:00—18:45
Antibodies for the Treatment of Infectious Diseases
Meeting has ended...abstracts no longer viewable online.

Macdonald ABC
Leo James, MRC Laboratory of Molecular Biology, UK
Intracellular Antibody Immunity and the Cytosolic Fc Receptor TRIM21

Carole A. Bewley, National Institutes of Health, USA
Antibody-like Properties and Functions of Antiviral Carbohydrate Binding Proteins

18:45—19:00
The Human Vaccines Project: A Roadmap to Effective Cancer Vaccine and Immunotherapeutic Development
Meeting has ended...abstracts no longer viewable online.

Macdonald DEF
* A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA

Theodore Schenkelberg, Human Vaccines Project, USA


Following Session is for Antibodies as Drugs (X2)

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Macdonald ABC
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Frontenac

FRIDAY, MARCH 11

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

Regeneron Pharmaceuticals, Inc.

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Dove Medical Press Ltd

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


Juno Therapeutics


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676